Why the study?
Does apixaban reduce the risk of stroke/systemic embolism and major bleeding compared to rivaroxaban, dabigatran, or warfarin in elderly patients with nonvalvular atrial fibrillation?
Does apixaban reduce the risk of stroke/systemic embolism and major bleeding compared to rivaroxaban, dabigatran, or warfarin in elderly patients with nonvalvular atrial fibrillation?
In a real-world cohort of elderly patients with nonvalvular atrial fibrillation, apixaban was associated with significantly lower risks of stroke/systemic embolism and major bleeding compared to rivaroxaban and warfarin.
No takes yet. Share an insight, caveat, or question.
Apixaban may lower S/SE and MB risks in elderly NVAF; leaves open need for randomized confirmation before practice change.
Deitelzweig et al. (2017) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: